10 results about "Adjuvant chemotherapy" patented technology

A hybrid liver cancer prognosis model, prognosis system and medium, the model takes independent influence factors as input and outputs hybrid liver cancer postoperative risk scores, the hybrid liver cancer postoperative risk scores are used for dividing risk levels, and the risk levels are used for hybrid liver cancer prognosis evaluation. And / or is used for postoperative adjuvant chemotherapy decision-making of mixed liver cancer. The hybrid liver cancer prognosis model is jointly constructed by combining the traditional clinical pathological characteristics and immune microenvironment indexes, the key effect of the tumor immune microenvironment in CHC prognosis is indicated, and the constructed hybrid liver cancer prognosis model has good CHC prognosis prediction performance; in addition, decisions of postoperative adjuvant chemotherapy can be provided for patients with different risk levels, precise treatment of the CHC patients is achieved, and long-term survival prognosis of the CHC patients is improved.

The invention discloses a deep learning-based lung cancer adjuvant chemotherapy benefited patient identification method and system, and relates to the technical field of lung cancer precise treatment and artificial intelligence crossing, and the method comprises the steps: analyzing and preprocessing preoperative and postoperative registration logs of a patient to obtain basic information of the patient, a pathological image of the patient and a treatment strategy of the patient; the method comprises the following steps: performing segmentation processing on a patient pathological image by adopting nnformer to obtain a focus region segmented image, performing feature extraction and enhancement on the focus region segmented image to obtain image omics features, and constructing an improved 3D survival analysis model; and analyzing the basic information of the patient, the radiomics characteristics and the treatment strategy of the patient by adopting an improved 3D survival analysis model to obtain an identification result of the lung cancer adjuvant chemotherapy benefited patient. According to the method, the quantitative survival risk score and the adjuvant chemotherapy sensitivity conclusion are output, and an interpretable reference basis is provided for clinical decision making.

This invention belongs to the field of traditional Chinese medicine technology, specifically relating to the application of a formula for nourishing vital energy and strengthening the body in reducing the toxicity of adjuvant chemotherapy after radical resection of non-small cell lung cancer. This invention discloses a formula for nourishing vital energy and strengthening the body, characterized in that it is composed of the following components by weight: 15-30 parts raw Astragalus membranaceus, 9-21 parts prepared Rehmannia glutinosa, 15-30 parts stir-fried Dioscorea opposita, 9-15 parts Atractylodes macrocephala, 9-15 parts Poria cocos, 15-30 parts raw Coix lacryma-jobi, 9-15 parts Ophiopogon japonicus, 9-15 parts Asparagus cochinchinensis, 15-30 parts Adenophora stricta, 9-15 parts Ligustrum lucidum, 9-15 parts Eclipta prostrata, 9-15 parts stir-fried germinated barley, 9-15 parts stir-fried malt, and 3-6 parts prepared Glycyrrhiza uralensis. This invention can restore vital energy, reverse postoperative weakness, build a foundation for chemotherapy tolerance to reduce toxic side effects, improve chemotherapy tolerance, reduce the risk of interruption to ensure efficacy, improve quality of life during chemotherapy, and help prolong postoperative survival.

According to the technical scheme, the pancreatic cancer prognosis prediction system based on deep learning is characterized by comprising a data input module, a preprocessing module, a feature extraction module, a cross sequence attention fusion module and a multi-task prediction module. The system disclosed by the invention can accurately predict the overall lifetime (OS) and the disease-free lifetime (DFS) of the patient by analyzing the preoperative multi-sequence magnetic resonance imaging (MRI) image of the patient, and carries out risk stratification. More importantly, clinical doctors can be guided to formulate personalized adjuvant therapy schemes for patients with different risk levels, for example, whether the patients can benefit from postoperative adjuvant chemotherapy or immunotherapy or not is judged, and therefore precise medical treatment is achieved, the treatment effect is improved, and invalid treatment is avoided.

The invention provides a marker, a kit containing the marker, application of the marker and a use method of the marker. The marker comprises at least one selected from the group consisting of MUC1, MUC5AC, and Claudin18.2. The invention also relates to a method for preparing the marker. The marker and the kit containing the marker can be used for predicting prognosis of the intrahepatic cholangiocarcinoma, predicting the curative effect of targeted therapy and postoperative adjuvant therapy on the intrahepatic cholangiocarcinoma based on tumor expression states, and performing classified prediction on a big bile duct type and a small bile duct type of the intrahepatic cholangiocarcinoma. The disclosure also provides a method of cancer prognosis comprising detecting the expression of the marker and predicting the degree of benefit from post-operative adjuvant therapy in a subject, and / or the prognosis of cancer, particularly intrahepatic cholangiocarcinoma, in a subject. The present disclosure provides universal markers that can be used to predict the efficacy of postoperative adjuvant therapy, such as postoperative adjuvant chemotherapy, on intrahepatic cholangiocarcinoma.

The invention relates to a polypeptide for neoadjuvant chemotherapy and postoperative adjuvant chemotherapy of colorectal cancer and application of the polypeptide. The polypeptide is Pep-NDFIP2, and the amino acid sequence of the polypeptide is as shown in SEQ ID No. 1; the Pep-NDFIP2 can be used for improving the sensitivity of colorectal cancer cells when the colorectal cancer cells face neoadjuvant chemotherapy and postoperative adjuvant chemotherapy, so that a chemotherapy sensitization effect is achieved in the neoadjuvant chemotherapy and postoperative adjuvant chemotherapy processes of the colorectal cancer. In addition, the Pep-NDFIP2 is easy to prepare and purify in vitro, is convenient for clinical popularization and application, and is expected to improve the overall prognosis of colorectal cancer patients and improve the treatment benefit. Therefore, the Pep-NDFIP2 has potential commercial and industrial values, and can be widely applied to the technical field of treatment related to neoadjuvant chemotherapy and postoperative adjuvant chemotherapy of tumors, especially colorectal cancer.

The application provides a protein marker for predicting the sensitivity of adjuvant chemotherapy of an ovarian cancer patient and an application, based on proteomics data of an ovarian cancer tissue sample, combining a preliminary screening model and a classification model and PRM technology, screening a plurality of protein markers with representative meanings for predicting the sensitivity of adjuvant chemotherapy of an ovarian cancer patient after neoadjuvant therapy, training an ovarian cancer patient chemotherapy sensitivity prediction model by using the screened protein markers, predicting the chemotherapy sensitivity of an ovarian cancer patient who has not undergone adjuvant therapy by using the ovarian cancer patient chemotherapy sensitivity prediction model, if the chemotherapy sensitivity is low, it means that the probability of recurrence of the patient after 6 months of adjuvant therapy is high, so medical staff can adjust the treatment plan accordingly, avoid unnecessary chemotherapy treatment for ovarian cancer patients, and play a preventive effect.

A system for predicting breast cancer response to neo-adjuvant chemotherapy (NAC) using quantitative ultrasound (QUS) parametric images and / or B-mode images, the system comprising: an imaging system for acquiring at least one ultrasound data frame comprising a raw RF signal, and / or an image; with a computer system performing the operations of: receiving the at least one ultrasound data frame and using one or more predefined rules to identify a region of interest (ROI) in each of the at least one ultrasound data frame; generating at least one quantitative ultrasound (QUS) parametric map and / or processed B-mode image for the tumor; with a feature network of a machine learning architecture, extracting optimal feature maps from the QUS parametric images and / or B-mode images; and classifying the tumor subject into a responder or a non-responder to the NAC.

This invention discloses a traditional Chinese medicine compound for adjuvant chemotherapy in colorectal cancer and its preparation method. The compound is made from the following raw materials in parts by weight: 15-30 parts of Polygonum cuspidatum and 10-20 parts of Citrus aurantium. The preparation method includes: purification treatment, physical primary cell wall disruption, sonic-enzyme synergistic deep cell wall disruption, enzyme inactivation and stabilization, extraction process, concentration process, alcohol precipitation purification, macroporous resin-directed debittering, multi-component complex molecular inclusion, bitter taste receptor antagonism and synergistic taste correction, drying and shaping. This invention's compound, through the precise combination of Polygonum cuspidatum and Citrus aurantium, achieves multi-target synergistic effects, which can reduce the toxic side effects of chemotherapy, enhance the killing effect of chemotherapy on tumors, directly inhibit the proliferation, migration, and invasion of colorectal cancer cells, improve the tumor microenvironment, and reverse chemotherapy resistance. This invention has the advantages of significant chemotherapy synergistic effect, clear toxicity reduction effect, high safety, and wide clinical applicability, and is suitable for adjuvant chemotherapy treatment of colorectal cancer.

The invention discloses application of HER-2 combined with a three-level lymph structure in diagnosis and treatment of mixed hepatocyte-bile duct cell carcinoma. A prognosis evaluation system and a treatment decision mode constructed on the basis of HER-2 detection are beneficial to establishment of a standard cHCC-CCA prognosis system, and the HER-2 detection can adopt a clinical conventional immunohistochemical method and is directly in butt joint with an existing pathological examination process, so that the clinical transformation threshold is effectively reduced, and the clinical treatment efficiency is improved. The clinical practicability and operability are obvious. Meanwhile, the expression level of HER-2 can reflect whether the patient can directly benefit from adjuvant chemotherapy, so that treatment schemes can be quickly generated for different patients after pathological examination. Moreover, the invention also discloses the association between the HER-2 and the tumor immune microenvironment, and provides a new thought for developing HER-2 and TLS combined prognosis products and targeted drug combined immunotherapy strategies.